Effectiveness of Nutrition Education Program and Omega-3 Supplementation Among Non-alcoholic Fatty Liver Disease Patients

Launched by HAWLER MEDICAL UNIVERSITY · Oct 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a nutrition education program and omega-3 supplements might help people with non-alcoholic fatty liver disease (NAFLD). The researchers want to see if these approaches can improve important health markers, like body weight, liver function, and cholesterol levels. Participants will be placed into different groups to either receive nutrition education, take omega-3 supplements, or be part of a control group without these interventions.

To join the study, participants need to be between 18 and 74 years old and have been diagnosed with mild to moderate NAFLD through an ultrasound. They should also be comfortable using a mobile phone. However, some individuals may not be eligible, including those who have taken omega-3 supplements in the past six months, are pregnant or breastfeeding, or have other serious health conditions. Those who participate can expect to learn about healthy eating and possibly see improvements in their liver health and weight over time. The trial is not yet recruiting participants, so there will be more updates in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18-74 years' old.
• • Ability to use a mobile phone.
• • Ultrasound examination diagnosed Patients with grade 1 and 2 non-alcoholic fatty liver disease.
• Exclusion Criteria:
• • supplementary intakes of n-3 PUFA within the previous 6 months.
• • pregnancy or breastfeeding.
• • chronic liver disease of other causes (autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, hereditary haemochromatosis, Wilson's disease, a1-anti-trypsin deficiency, coeliac disease).
• • hormone therapy and use of drugs like amiodarone, methotrexate, and corticosteroid.
• • three months.
• • chronic disease such as cardiovascular, gastrointestinal, thyroid, renal, cancer or pancreatic that assessed by a specialist.
• • The use of drugs known to be associated with liver steatosis (Drugs known to be capable of inducing steatosis and steatohepatitis can be divided into three broad groups: those that cause steatosis and steatohepatitis independently (e.g., amiodarone, perhexiline maleate); drugs which can precipitate latent NASH (e.g., tamoxifen); drugs which induce sporadic events of steatosis/steatohepatitis (e.g., carbamazepine).